Chronic Hypoparathyroidism clinical trials

Explore recruiting chronic hypoparathyroidism clinical trials.

Recruiting chronic hypoparathyroidism studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Hypoparathyroidism trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism

Germany, France, Romania, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Italy, Netherlands, Denmark, Belgium, France, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic Hypoparathyroidism trials by city

Chronic Hypoparathyroidism clinical trials

Recruiting chronic hypoparathyroidism studies right now

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

Also recruiting in Europe

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Chronic Hypoparathyroidism trials by city

Other conditions